Rate and Predictors of Relapse in the Treatment of Hepatitis C in Real-Life Clinical Practice in Spanish Hospitals (FAST-4).

Trial Profile

Rate and Predictors of Relapse in the Treatment of Hepatitis C in Real-Life Clinical Practice in Spanish Hospitals (FAST-4).

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Jul 2012

At a glance

  • Drugs Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms FAST-4
  • Sponsors Merck & Co; Schering-Plough
  • Most Recent Events

    • 22 Apr 2012 Actual patient number changed from 278 to 279 as reported by ClinicalTrials.gov.
    • 11 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Jan 2011 Planned end date changed from 1 Jan 2011 to 1 Feb 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top